Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CC-93538 in eosinophilic esophagitis
jRCT2051200140Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing CC-93538 with Placebo (2 arms). Primary endpoints: Change in dysphagia days clinical response and Eosinophil histologic response at 6 or fewer eosinophils per high-power field. Started Jul 2021; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on jRCT2051200140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200140.